# Timothy Campbell

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/timothy-campbell/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,089 |
| Field | CAR-T cell therapy research |
| h-index | 26 |
| i10-index | 42 |
| Last Known Institution | Bristol-Myers Squibb (United States) |
| OpenAlex ID | https://openalex.org/A5008762690 |
| ORCID iD | 0000-0002-3538-8784 |
| Works | 171 |

## Researcher papers

- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist](https://scholariq.org/papers/rapid-mobilization-of-murine-and-human-hematopoietic-stem-and-progenitor-cells/)
- [Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma](https://scholariq.org/papers/biallelic-loss-of-bcma-as-a-resistance-mechanism-to-car-t-cell-therapy-in-a/)
- [Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities](https://scholariq.org/papers/normal-and-leukemic-stem-cell-niches-insights-and-therapeutic-opportunities/)
- [Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis](https://scholariq.org/papers/dipeptidylpeptidase-4-negatively-regulates-colony-stimulating-factor-activity/)
- [Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial](https://scholariq.org/papers/idecabtagene-vicleucel-for-relapsed-and-refractory-multiple-myeloma-post-hoc-18/)
- [Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.](https://scholariq.org/papers/idecabtagene-vicleucel-ide-cel-bb2121-a-bcma-targeted-car-t-cell-therapy-in/)
- [Inhibition of CD26 in Human Cord Blood CD34 <sup>+</sup> Cells Enhances Their Engraftment of Nonobese Diabetic/Severe Combined Immunodeficiency Mice](https://scholariq.org/papers/inhibition-of-cd26-in-human-cord-blood-cd34-sup-sup-cells-enhances-their/)
- [AMD3100 and CD26 Modulate Mobilization, Engraftment, and Survival of Hematopoietic Stem and Progenitor Cells Mediated by the SDF‐1/CXCL12‐CXCR4 Axis](https://scholariq.org/papers/amd3100-and-cd26-modulate-mobilization-engraftment-and-survival-of-hematopoietic/)
- [Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial](https://scholariq.org/papers/analysis-of-patient-reported-experiences-up-to-2-years-after-receiving/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Bristol-Myers Squibb (United States)](https://scholariq.org/institutions/bristol-myers-squibb-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.